Abstract 172P
Background
Lenvatinib is the first-line treatment for advanced hepatocellular carcinoma (HCC), but the prognosis was still unsatisfactory. Recently, hepatic arterial infusion chemotherapy (HAIC), and immune checkpoint inhibitors have shown promising results for patients with advanced HCC. Considering different anti-malignancy mechanisms, combining these three modalities may improve outcomes. This study was to compare the efficacy and safety of lenvatinib, toripalimab, plus HAIC versus lenvatinib alone for advanced HCC patients.
Methods
This was a retrospective study including patients treated with lenvatinib alone (8 mg [≤60kg] or 12mg [>60kg] once daily) or lenvatinib, toripalimab plus HAIC (LeToHAIC group, lenvatinib once daily 0-1 week prior to initial HAIC, 240 mg toripalimab 0-1 day prior to every HAIC cycle, and HAIC with FOLFOX regimen [oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, fluorouracil bolus 400 mg/m2 on day 1, and fluorouracil infusion 2400 mg/m2 for 46 hours, every 3 weeks]). Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR) and treatment-related adverse event (TRAE) were compared.
Results
From February 2019 to August 2019, 157 patients were included for this study: 71 in the LeToHAIC group, and 86 in the lenvatinib group. The LeToHAIC group showed a longer PFS (11.1 vs 5.1 months, p<0.001), a longer OS (not reached vs 11 months, p<0.001), a higher DCR (RECIST or mRECIST: 90.1% vs 72.1%, p=0.005), a higher ORR (RECIST: 59.2% vs 9.3%, p<0.001; mRECIST: 67.6% vs 16.3%, p<0.001) than the lenvatinib group. In addition, 14.1% of patients in the LeToHAIC group achieved complete response by mRECIST criteria. Grade 3/4 TRAEs that were more frequent in the LeToHAIC group than in the lenvatinib group included neutropenia (8.5% vs 1.2%), thrombocytopenia (5.6% vs 0), and nausea (5.6% vs 0).
Conclusions
Triple combination therapy of lenvatinib, toripalimab, and HAIC had acceptable toxic effects and might improve survival compared with lenvatinib alone in advanced HCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Natural Science Foundation of China Ministry of Science and Technology of the People's Republic of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
163P - Gastrointestinal stromal tumours (GIST) in adolescents and young adults (AYA) in an Asian institution from 2002 to 2018
Presenter: Evelyn Yi Ting Wong
Session: e-Poster Display Session
164P - The impact of sarcopenia on chemotherapy toxicity and survival rate among hepatocellular carcinoma patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Elizabeth Marcella
Session: e-Poster Display Session
165P - Prognostic factors in sorafenib-treated hepatocellular carcinoma: Multicentre analysis of a European population sample
Presenter: João Gramaça
Session: e-Poster Display Session
166P - Differences and similarities in presentation and management patterns in patients with hepatocellular carcinoma (HCC) across Hong Kong, Singapore and Thailand
Presenter: Pierce Chow
Session: e-Poster Display Session
167P - Epidemiology of hepatocellular carcinoma (HCC) in tertiary level hospitals in Bangladesh
Presenter: Abdullah Al Mamun Khan
Session: e-Poster Display Session
168P - Response assessments in hepatocellular carcinoma: What are the best criteria to utilize? mRECIST or RECIST 1.1? A retrospective meta-analysis of multiple phase III trials
Presenter: Oliver Bohnsack
Session: e-Poster Display Session
169P - IMbrave150: Management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCC
Presenter: Masatoshi Kudo
Session: e-Poster Display Session
170P - Sintilimab plus anlotinib as first-line therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC)
Presenter: Xiaofeng Chen
Session: e-Poster Display Session
171P - Transarterial chemoembolization (TACE) plus lenvatinib versus TACE plus sorafenib for hepatocellular carcinoma (HCC) with portal vein tumour thrombus (PVTT): A prospective randomized study
Presenter: Xiaoyan Ding
Session: e-Poster Display Session
173P - Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Asia: Interim results from the observational REFINE study
Presenter: Ho Yeong Lim
Session: e-Poster Display Session